查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835063

女性用避孕市場依產品類型、機制、最終用戶年齡和通路分類－2025-2032 年全球預測

Female Contraceptive Market by Product Type, Mechanism, End User Age, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，女性用避孕市場規模將成長至 165.3 億美元，複合年成長率為 6.60%。

主要市場統計數據
基準年2024年 99.1億美元
預計2025年 105.7億美元
預測年份：2032年 165.3億美元
複合年成長率（%） 6.60%

策略介紹，闡述影響現代女性用避孕器決策的臨床進展、相關人員的優先事項和獲取限制

隨著臨床創新、醫療服務提供者的轉變以及患者期望的不斷變化，女性避孕的格局正在迅速演變。本報告首先簡要闡述了當代環境，重點介紹了臨床模式、分銷現狀、監管壓力以及影響醫療機構避孕可及性和採用率的實際限制因素。報告還將觀察到的醫療服務提供者偏好和患者決策模式與設備和藥物選擇的最新進展相結合，為企業高管和臨床領導者奠定了實用的知識基準。

引言部分重點闡述了技術改進、以患者為中心的醫療模式和供應鏈韌性如何相互交織，從而確定了最有價值的投資和營運重點，從而將競爭格局置於背景之中。引言也明確了關鍵的相關人員群體（製造商、臨床醫生、相關人員、採購團隊和病患權益組織），並闡明了每個群體所掌控的決策槓桿。該框架將幫助讀者理解後續章節，包括結構性變化、政策影響、細分市場細微差別、區域動態和建議行動。

分析概述了正在重塑避孕實踐模式和患者在醫療環境中獲取避孕藥具的臨床、監管和數位力量的融合

一系列變革力量正在重塑女性避孕領域，這些力量正在改變臨床實踐、產品開發和患者的選擇。新的設備設計和長效製劑正在為各個生殖生命階段的臨床選擇提供更多選擇，並促使臨床醫生重新思考諮詢工作流程和追蹤通訊協定。同時，數位健康工具和遠端醫療已開始改變避孕諮詢、配藥和追蹤的提供方式，減少了地域差異，並使患者能夠自主選擇避孕方法。

除了技術和醫療服務的變化之外，監管途徑和證據預期也在不斷演變，這提高了臨床數據的標準，同時也明確了產品標籤擴展和新適應症的窗口期。隨著各公司追求差異化的價值提案，強調易用性、副作用概況和整合的護理體驗，而非僅僅在價格上競爭，競爭動態正在改變。最後，付款方方式和公共衛生優先事項越來越注重可及性和依從性支持計畫的公平性，這促使相關人員設計解決方案，以解決持續和適當使用避孕藥具的系統性障礙。這些轉變，加上持續的普及，需要整合商業和臨床策略，以協調產品差異化、報銷參與和醫療機構教育。

全面分析2025年關稅調整將如何重塑避孕藥具的供應鏈、籌資策略與定價壓力

2025年的政策環境引入了影響進口藥品投入和設備零件的關稅調整，這些變化對採購、定價動態和供應鏈配置產生了複合影響。依賴國際採購電子元件製造可植入設備或依賴海外生產的原料藥的製造商面臨著直接的利潤壓力，引發了關於近岸外包、供應商多元化和庫存策略的討論。採購負責人和醫院系統正在透過審查供應商合約並探索更長的採購期限來應對波動。

這些關稅主導的成本壓力也影響產品生命週期決策。開發團隊優先考慮流程效率和供應商整合，以便在更高的落地成本下也能維持產品可行性。同時，預算有限的公共衛生項目和安全網提供者正在探索補充資金模式和採購聯盟，以維持產品的可及性，特別是對於需要專門植入培訓和設備供應的長效可逆避孕藥。重要的是，一些製造商已加快步伐，透過在地化關鍵投入品的生產，並重新設計包裝和物流，以提高韌性並縮短前置作業時間，從而降低跨境關稅的影響。

從需求角度來看，臨床醫生和採購主管指出，在製劑和採購指南受到嚴格限制的環境下，即使交付成本略有上漲，也會影響諮詢偏好。因此，商業團隊必須將資費方案納入採購談判、定價策略和價值溝通中，強調醫療總成本、依從性偏好，從而引起付款人和機構買家的共鳴。實現供應鏈多元化並向區域產能轉移是一項需要多年努力的工作，但在不斷變化的貿易環境中，穩定醫療資源取得並保持競爭力正日益成為當務之急。

將產品類型、荷爾蒙機制、年齡層和分銷管道聯繫起來的詳細細分洞察，以揭示臨床和商業結合的目標機會

有效的細分可以揭示避孕生態系中臨床效益、病人偏好和機會的交會點。植入、注射、避孕器和避孕藥是核心臨床類別，每種類別都有不同的給藥途徑和遵從性。對於避孕器，區分含銅和荷爾蒙的配方會影響副作用管理、有效持續時間和提供者訓練。避孕藥有複方製劑和僅含黃體素的配方，即使是複方製劑，不同世代之間也有差異。第一代、第二代、第三代和第四代藥物各有其獨特的功效和耐受性權衡，影響配方師的選擇。

按機制細分，透過區分荷爾蒙療法和非荷爾蒙療法選項，並認知到荷爾蒙療法選項分為組合藥物製劑和僅含孕激素的製劑，具有不同的禁忌症和諮詢需求，進一步明確了需求動態。 15-24 歲族群優先考慮自主性、便利性和隱私性；25-34 歲族群通常會在計劃生育目標與職業和生活方式之間取得平衡；35-49 歲族群優先考慮長期療效、併發症考量以及過渡到合適的非動態選項。分銷管道塑造了獲取途徑，診所、醫院藥房、線上藥房和零售藥房各自描述了明確的摩擦點以及教育、依從性支援和後續護理的機會。

整合這些細分市場，可以揭示哪些有針對性的干涉措施可以提高藥物的採用率和留存率。例如，長效製劑可能與尋求最低維護的老年人群產生強烈共鳴，而數位諮詢和郵購配送則可以顯著降低優先考慮謹慎的年輕用戶的獲取門檻。同樣，根據特定機制的安全考慮客製化溝通方式，並確保分銷管道支援藥物的插入和給藥，也是關鍵的營運重點。透過在產品類型、機制、年齡和分銷管道的交叉領域協調產品差異化、臨床證據產生和通路賦能，相關人員可以製定更有針對性、更有效的策略，以兼顧臨床結果和使用者體驗。

比較美洲、中東和非洲以及亞太地區影響取得途徑、監管途徑和分銷策略的關鍵區域動態和政策

地理動態影響藥物的可及性、監管途徑和競爭行為，為每個地區帶來了獨特的限制和機會。在美洲，政策爭議、付款人結構和多樣化的醫療服務提供者網路既為資源充足的醫療體系中的快速商業化創造了機會，也為服務不足的人群帶來了持續的可及性挑戰。區域採購舉措和計劃計畫決定了公共醫療機構對藥物的接受程度，而與私人付款人的談判則決定了產品在高報銷水平環境中的佈局。

歐洲、中東和非洲呈現出複雜的法規環境和能力差異。在這一廣大區域內，一些國家擁有高度集中的採購和嚴格的監管協調，一旦獲得核准，即可進行協調部署。其他市場則呈現細分化，不同的臨床實務模式和基礎設施影響器械避孕器的可行性。獲取計畫和國際捐助舉措在推動長效可逆避孕措施的廣泛傳播方面仍然發揮著重要作用，尤其是在資源匱乏的地區。

亞太地區擁有雄厚的製造能力，國內需求快速成長。一些司法管轄區的監管機構正在加快避孕產品的審查，並培養本地製造能力，從而縮短前置作業時間，並增加對國際貿易波動的承受能力。然而，文化因素、醫療保健提供者的執業規範以及差異化的報銷格局仍然影響著採用曲線。在所有地區，相關人員必須根據當地的法律規範、分銷生態系統以及影響採購和患者可及性的政策重點調整其商業化策略。

對製造商、設備專家和敏捷參與企業如何透過臨床證據、夥伴關係和供應鏈彈性實現差異化進行實際分析

競爭格局由傳統製藥公司、單一業務設備製造商以及利用服務和數位生態系統來提升可及性的新參與企業組成。領先的公司專注於研發，以提高耐受性和易用性，同時投資培訓項目，幫助臨床醫生掌握設備插入和追蹤技能。製造商與臨床網路之間的策略夥伴關係正成為一種可行的途徑，透過將產品供應與醫療保健提供者的教育和病患支援服務相結合，加速醫療應用。

規模較小、更敏捷的公司正憑藉創新的交付機制、患者參與工具以及針對特定年齡層或臨床亞群的利基策略脫穎而出。製造外包聯盟和集團採購組織正在透過談判長期供應協議來增強影響力，這凸顯了可預測的供應和基於價值的合約對於商業性成功的重要性。

總體而言，成功的公司將能夠將產品屬性與可證明的臨床和經濟效益相結合，投資於上市後和現實世界證據，並建立涵蓋臨床醫生培訓和患者支持的綜合價值命題。在製造、監管策略和分銷方面的卓越營運也同樣重要；這些環節的中斷會迅速削弱醫療保健買家和臨床醫生的信任。

製造商和醫療系統領導者可採取的策略重點，以協調證據產生、彈性供應鏈和特定管道的商業性執行

產業領導者應在臨床證據產生、供應鏈韌性和特定管道商業化之間採取協調一致的策略。首先，投資於可靠的比較安全性和耐受性數據，這些數據能夠直接解決臨床醫生的擔憂並反映患者相關的療效，並將這些證據與簡潔易懂、方便臨床醫生使用的教育模組相結合，以加速基於器械的治療和長效治療方案的順利應用。其次，優先考慮供應商多元化，並考慮投資區域製造或與製造外包製造商合作，以降低貿易政策變化和投入成本波動帶來的風險。

第三，我們將根據分銷現狀調整市場策略，為診所提供入職培訓和庫存解決方案，為醫院藥房提供處方箋和總醫療成本解決方案，並透過謹慎包裝和遠端醫療諮詢服務，最佳化我們的線上管道，以滿足更年輕、更注重隱私的人群的需求。第四，我們將積極與付款人和公共衛生採購方溝通，強調持續照護、減少意外懷孕和生命週期依從性支持，而不僅僅是單價。最後，我們將實施真實世界證據計畫和上市後安全監測，以維護監管信心並長期提升我們的產品定位。這些措施將打造一個兼顧臨床可信度、營運韌性和管道有效性的持久成長平台。

我們透明的調查方法結合了主要相關人員訪談、監管和臨床證據審查以及供應鏈分析，以形成策略見解

本研究整合了對臨床醫生、採購官員、臨床專案經理和行業高管的初步定性訪談，並結合了對監管備案文件、臨床試驗註冊中心以及主要醫療機構公開指南的結構化審查。受訪者來自不同的地理、醫療機構和職位，旨在提供關於臨床實踐、採購考量和患者體驗的客觀視角。次要分析著重於政策公告、資費變化和供應鏈指標，以了解其對製造商和買家的營運影響。

資料綜合採用主題分析，揭示政策、供應鏈彈性、臨床應用和病患行為之間的交叉趨勢和因果關係。用例描述了在供應商培訓、籌資策略和管道賦能方面的成功干預措施。在適當情況下，納入了敏感性考慮，以強調貿易政策、監管要求和臨床指南的變化如何改變建議的優先事項。調查方法強調資訊來源類型的透明度和跨多個證據流的三角測量，以支持本報告中提出的策略建議。

結論性結論將創新、准入障礙和將產品進步轉化為臨床影響所需的營運重點聯繫起來

總而言之，女性用避孕領域面臨臨床創新和系統可近性的雙重挑戰，需要商業性、臨床和營運層面的綜合應對。器械設計和配方的進步擴大了最終用戶的選擇，但其應用取決於臨床醫生的舒適度、分銷能力和報銷靈活性的相互作用。不斷變化的貿易政策和關稅調整使得供應鏈策略和區域生產考量日益重要，進而影響採購行為和產品定位。

為了應對這種環境，相關人員群體的生活現實來客製化通路策略。將研發、監管事務、商業策略和供應鏈管理連結起來的跨職能規劃，對於將產品創新轉化為持續的可及性和臨床效益至關重要。本報告中的見解旨在為此類決策提供參考，並為有針對性的投資和夥伴關係提供實務基礎。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 消費者對具有數位週期追蹤功能的非荷爾蒙避孕設備的需求不斷增加
  • 遠距避孕遠端醫療諮詢激增，改善了服務不足地區的避孕服務
  • 可生物分解和無激素植入材料的進步減少了副作用和環境廢棄物
  • 將基於人工智慧的生育預測工具整合到個人化避孕計畫中
  • 男性避孕研究的擴展正在改變傳統的市場動態和性別角色
  • 監管部門加速下一代避孕環和經皮吸收貼片產品核可
  • 數位健康Start-Ups與製藥公司合作開發自我調整避孕解決方案

第6章 2025年美國關稅的累積影響

第7章 人工智慧的累積影響，2025年

第8章女性用避孕藥市場（依產品類型）

  • 植入
  • 注射
  • 子宮內避孕器
    • 銅子宮內避孕器
    • 荷爾蒙子宮內避孕器
  • 丸
    • 複方藥丸
      • 第一代
      • 第四代
      • 第二代
      • 第三代
    • 僅含黃體素的藥丸

第9章女性用避孕藥市場（按機制）

  • 荷爾蒙
    • 組合
    • 僅含黃體素
  • 非荷爾蒙

第 10 章。以最終用戶年齡層別分類的女性用避孕藥市場

  • 15至24歲
  • 25-34歲
  • 35至49歲

第11章女性用避孕藥市場按分銷管道

  • 診所
  • 醫院藥房
  • 網路藥局
  • 零售藥局

第12章女性用避孕藥市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章女性用避孕藥市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章女性用避孕藥市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Bayer Aktiengesellschaft
    • Organon & Co.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Johnson & Johnson
    • AbbVie Inc.
    • Viatris Inc.
    • Perrigo Company plc
    • Gedeon Richter Plc
    • Novartis AG
Product Code: MRR-4348D129FB2D

The Female Contraceptive Market is projected to grow by USD 16.53 billion at a CAGR of 6.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.91 billion
Estimated Year [2025] USD 10.57 billion
Forecast Year [2032] USD 16.53 billion
CAGR (%) 6.60%

A strategic introduction that frames clinical advances, stakeholder priorities, and access constraints shaping contemporary female contraceptive decision making

The contraceptive landscape for women is undergoing rapid evolution as clinical innovation, shifting provider practices, and changing patient expectations converge. This report opens with a concise framing of the contemporary environment, highlighting clinical modalities, distribution realities, regulatory pressures, and the practical constraints that shape access and adoption across care settings. It sets a pragmatic intellectual baseline for executives and clinical leaders by integrating recent advances in device and pharmaceutical options with observed patterns in provider preferences and patient decision-making.

The introduction contextualizes the competitive environment by emphasizing how technological improvements, patient-centered care models, and supply chain resilience intersect to determine where investment and operational attention are most valuable. It also clarifies the principal stakeholder groups-manufacturers, clinicians, payors, procurement teams, and patient advocacy organizations-and articulates the decision levers each group controls. Taken together, the framing prepares readers to interpret subsequent sections on structural shifts, policy impacts, segmentation nuances, regional dynamics, and recommended actions.

An analytical overview of the converging clinical, regulatory, and digital forces that are reshaping contraceptive practice patterns and patient access across care settings

The landscape for female contraception is being reshaped by a set of transformative forces that alter clinical practice, product development, and patient choice. New device designs and longer-acting formulations have expanded clinical options for different reproductive life stages, prompting clinicians to rethink counseling workflows and follow-up protocols. Concurrently, digital health tools and telemedicine have begun to change how contraceptive counseling, prescription, and follow-up are delivered, reducing geographic friction and enabling more patient autonomy in method selection.

In addition to technological and care-delivery changes, regulatory pathways and evidence expectations have evolved, raising the bar for clinical data but also creating clearer windows for incremental label expansions and novel indications. Competitive dynamics are shifting as firms pursue differentiated value propositions that emphasize ease of use, side effect profiles, and integrated care experiences rather than simple price competition. Finally, payor approaches and public health priorities are increasingly attentive to equity of access and adherence-support programs, encouraging stakeholders to design solutions that address systemic barriers to consistent, appropriate contraceptive use. Together, these shifts demand integrated commercial and clinical strategies that align product differentiation, reimbursement engagement, and provider education to capture sustained uptake.

A comprehensive analysis of how tariff adjustments in 2025 are reshaping supply chains, procurement strategies, and price pressures across contraceptive manufacturing and distribution

The policy environment in 2025 introduced tariff adjustments affecting imported pharmaceutical inputs and device components, and these changes have had compound effects on procurement, pricing dynamics, and supply chain configurations. Manufacturers that rely on internationally sourced electronic components for insertion devices or on active pharmaceutical ingredients produced abroad have faced immediate margin pressure, prompting discussions about nearshoring, supplier diversification, and inventory strategy. Purchasers and hospital systems have responded by revisiting supplier contracts and exploring longer cadence procurement arrangements to mitigate volatility.

These tariff-driven cost pressures have also influenced product lifecycle decisions. Development teams have increasingly prioritized process efficiencies and supplier consolidation to preserve product viability under higher landed costs. At the same time, public health programs and safety-net providers that operate on constrained budgets have sought supplemental funding models or procurement consortia to maintain access, particularly for long-acting reversible contraceptives that require specialized insertion training and device availability. Importantly, several manufacturers accelerated efforts to localize production of critical inputs and to redesign packaging and logistics to reduce cross-border tariff exposure, thereby enhancing resilience and shortening lead times.

From a demand perspective, clinicians and procurement leaders have indicated that even modest increases in delivered cost can influence method counseling preferences in settings where formularies and procurement guidelines are tightly restricted. Consequently, commercial teams must integrate tariff scenarios into procurement negotiations, pricing strategies, and value communications, highlighting total cost of care, adherence benefits, and downstream savings that resonate with payors and institutional buyers. Transitioning supply chains toward diversification and regional capacity represents a multi-year effort but one that is increasingly prioritized to stabilize access and maintain competitive positioning under shifting trade conditions.

In-depth segmentation insights that connect product types, hormonal mechanisms, age cohorts, and distribution channels to reveal targeted opportunities for clinical and commercial alignment

Effective segmentation illuminates where clinical benefit, patient preference, and commercial opportunity intersect within the contraceptive ecosystem. Product type distinctions remain essential: implants, injectables, intrauterine devices, and pills represent core clinical categories with distinct administration pathways and adherence profiles. Within intrauterine devices, the distinction between copper and hormonal options carries implications for side effect management, duration of effectiveness, and provider training. Pills encompass combined and progestin-only formulations, and within combined options there are generational differences-first, second, third, and fourth generation agents each present unique efficacy and tolerability trade-offs that influence prescriber selection.

Mechanism-based segmentation further clarifies demand dynamics by separating hormonal approaches from non-hormonal choices, and recognizing that hormonal options bifurcate into combined and progestin-only formulations with different contraindication profiles and counseling needs. Age-based end-user segmentation captures life-stage considerations: those aged 15 to 24 prioritize autonomy, convenience, and privacy; the 25 to 34 cohort often balances family planning goals with career and lifestyle considerations; and the 35 to 49 group places greater emphasis on long-term effectiveness, comorbidity considerations, and transition to non-hormonal alternatives as appropriate. Distribution channels shape access pathways, with clinics, hospital pharmacies, online pharmacies, and retail pharmacies each presenting distinct friction points and opportunities for education, adherence support, and aftercare.

Integrating these segmentation lenses reveals where targeted interventions can improve adoption and continuity. For example, long-acting modalities may resonate strongly with older age bands seeking minimal maintenance, while digital counseling and mail-order delivery can substantially lower access barriers for younger users who value discretion. Similarly, tailoring communications to mechanism-specific safety considerations and ensuring that distribution channels are equipped to support insertion or administration are critical operational priorities. By aligning product differentiation, clinical evidence generation, and channel enablement to the intersecting axes of product type, mechanism, age, and distribution, stakeholders can deploy more precise and effective strategies that address both clinical outcomes and user experience.

Key regional dynamics and policy contrasts across the Americas, Europe Middle East Africa, and Asia-Pacific that shape access, regulatory pathways, and distribution strategies

Geographic dynamics influence access, regulatory pathways, and competitive behavior across distinct regions, each presenting unique constraints and enablers. In the Americas, policy debates, payer structures, and diverse provider networks create both opportunities for rapid commercialization in well-resourced systems and ongoing access challenges in underserved populations. Regional procurement initiatives and advocacy programs have shaped uptake in public health clinics, while private payor negotiations dictate product positioning in higher-reimbursement settings.

Europe, Middle East & Africa presents a complex tapestry of regulatory environments and capacity differences. Some countries within this broad region have highly centralized procurement and stringent regulatory harmonization, enabling coordinated rollouts when approvals align. Other markets are fragmented, with variable clinical practice patterns and infrastructure that affect the feasibility of device-dependent contraceptives. Access programs and international donor initiatives remain influential in enabling broader distribution, especially for long-acting reversible methods in low-resource settings.

Asia-Pacific encompasses markets with substantial manufacturing capacity alongside rapidly evolving domestic demand. Regulatory agencies in several jurisdictions have accelerated reviews of contraceptive products and fostered local production capabilities, which can reduce lead times and exposure to international trade perturbations. However, cultural factors, provider practice norms, and heterogeneous reimbursement landscapes continue to shape adoption curves. Across all regions, stakeholders must adapt commercialization strategies to local regulatory structures, distribution ecosystems, and the policy priorities that influence procurement and patient access.

A practical analysis of how manufacturers, device specialists, and agile entrants are differentiating through clinical evidence, partnerships, and supply chain resilience

The competitive environment is populated by a mix of legacy pharmaceutical firms, specialized device manufacturers, and newer entrants leveraging service and digital ecosystems to enhance access. Leading firms focus R&D on improving tolerability and ease of use while investing in training programs to ensure clinician competence for device insertion and follow-up. Strategic partnerships between manufacturers and clinical networks have emerged as a pragmatic way to accelerate adoption, combining product supply with provider education and patient support services.

Smaller, agile companies are differentiating through novel delivery mechanisms, patient engagement tools, and targeted niche strategies aimed at specific age cohorts or clinical subpopulations. Contract manufacturing and component suppliers have also become pivotal players as firms seek to de-risk supply chains and maintain production flexibility. Additionally, procurement consortia and group purchasing organizations have increased their influence by negotiating longer-term supply agreements, which emphasizes the importance of predictable supply and value-based contracting for commercial success.

Across the competitive set, successful companies are those that link product attributes to demonstrable clinical and economic benefits, invest in post-market surveillance and real-world evidence, and create integrated value propositions that include clinician training and patient support. Operational excellence in manufacturing, regulatory strategy, and distribution is equally critical, as disruptions in any of those areas can quickly erode confidence among institutional buyers and clinicians.

Actionable strategic priorities for manufacturers and health system leaders to align evidence generation, resilient supply chains, and channel-specific commercial execution

Industry leaders should pursue a coordinated approach that aligns clinical evidence generation, supply chain resilience, and channel-specific commercialization. First, invest in robust comparative safety and tolerability data that speak directly to clinician concerns and patient-relevant outcomes, and pair that evidence with concise, clinician-friendly education modules to accelerate comfortable adoption of device-based and long-acting options. Second, prioritize supplier diversification and consider regional manufacturing investments or contract manufacturing partnerships to reduce exposure to trade policy shifts and input cost volatility.

Third, tailor go-to-market strategies to distribution realities by enabling clinics with insertion training and stocking solutions, supporting hospital pharmacies with formulary dossiers and total cost of care arguments, and optimizing online channels for privacy-focused younger cohorts through discreet packaging and telehealth-enabled counseling. Fourth, engage proactively with payors and public health purchasers using value narratives that emphasize continuity of care, reduced unintended pregnancies, and lifecycle adherence support rather than unit price alone. Finally, embed real-world evidence programs and post-market safety monitoring to sustain regulatory confidence and to refine product positioning over time. Taken together, these actions create a durable platform for growth that balances clinical credibility with operational resilience and channel effectiveness.

A transparent methodology combining primary stakeholder interviews, regulatory and clinical evidence review, and supply chain analysis to triangulate strategic insights

This research synthesizes primary qualitative interviews with clinicians, procurement directors, clinical program managers, and industry executives, coupled with a structured review of regulatory filings, clinical trial registries, and publicly available guidance from major health authorities. Interview subjects were selected to represent diverse geographies, care settings, and roles to provide a balanced view of clinical practice, procurement considerations, and patient experience. Secondary analysis focused on policy announcements, tariff changes, and supply chain indicators to contextualize operational implications for manufacturers and buyers.

Data synthesis employed thematic analysis to identify cross-cutting trends and causal linkages between policy, supply chain resilience, clinical adoption, and patient behavior. Case studies were used to illustrate successful interventions in provider training, procurement strategies, and channel enablement. Where appropriate, sensitivity considerations were discussed to highlight how changes in trade policy, regulatory requirements, or clinical guidelines could alter recommended priorities. The methodology emphasizes transparency in source types and triangulation across multiple evidence streams to support the strategic recommendations presented in this report.

A decisive conclusion drawing the connections between innovation, access barriers, and the operational priorities necessary to translate product advances into clinical impact

In conclusion, the female contraceptive space presents a blend of clinical innovation and systemic access challenges that require integrated commercial, clinical, and operational responses. Advances in device design and formulation expand options for end users, but adoption depends on the interplay of clinician comfort, distribution capacity, and reimbursement flexibility. Trade policy shifts and tariff adjustments have heightened the importance of supply chain strategy and regional production considerations, which in turn influence procurement behavior and product positioning.

To navigate this environment, stakeholders should prioritize evidence that aligns with clinician concerns, invest in resilient supply chains, and tailor channel strategies to the lived realities of different end-user cohorts. Coordinated cross-functional planning that connects R&D, regulatory affairs, commercial strategy, and supply chain management will be essential to translate product innovations into sustained access and clinical benefit. The insights in this report are intended to inform those decisions and to provide a practical foundation for targeted investments and partnerships.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing consumer demand for non-hormonal contraceptive devices with digital cycle-tracking integrations
  • 5.2. Surge in telehealth consultations for contraceptive care enhancing accessibility in underserved regions
  • 5.3. Advances in biodegradable and hormone-free implant materials reducing side effects and environmental waste
  • 5.4. Integration of artificial intelligence-powered fertility prediction tools into personalized contraceptive planning
  • 5.5. Expansion of male-focused contraceptive research shifting traditional market dynamics and gender roles
  • 5.6. Regulatory fast-tracking of next-generation vaginal rings and transdermal patches accelerating product approvals
  • 5.7. Collaborations between digital health startups and pharmaceutical firms for adaptive contraception solutions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Female Contraceptive Market, by Product Type

  • 8.1. Implants
  • 8.2. Injectables
  • 8.3. Intrauterine Devices
    • 8.3.1. Copper IUD
    • 8.3.2. Hormonal IUD
  • 8.4. Pills
    • 8.4.1. Combined Pill
      • 8.4.1.1. First Generation
      • 8.4.1.2. Fourth Generation
      • 8.4.1.3. Second Generation
      • 8.4.1.4. Third Generation
    • 8.4.2. Progestin Only Pill

9. Female Contraceptive Market, by Mechanism

  • 9.1. Hormonal
    • 9.1.1. Combined
    • 9.1.2. Progestin Only
  • 9.2. Non-Hormonal

10. Female Contraceptive Market, by End User Age

  • 10.1. 15-24 Years
  • 10.2. 25-34 Years
  • 10.3. 35-49 Years

11. Female Contraceptive Market, by Distribution Channel

  • 11.1. Clinics
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Female Contraceptive Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Female Contraceptive Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Female Contraceptive Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bayer Aktiengesellschaft
    • 15.3.2. Organon & Co.
    • 15.3.3. Teva Pharmaceutical Industries Ltd.
    • 15.3.4. Pfizer Inc.
    • 15.3.5. Johnson & Johnson
    • 15.3.6. AbbVie Inc.
    • 15.3.7. Viatris Inc.
    • 15.3.8. Perrigo Company plc
    • 15.3.9. Gedeon Richter Plc
    • 15.3.10. Novartis AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. FEMALE CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. FEMALE CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FEMALE CONTRACEPTIVE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 325. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. GCC FEMA